April 5, 2024 Release Highlights Copied
Practice Insights is pleased to announce updates in the application to support the Merit-Based Incentive Payment System (MIPS).
MIPS Quality Measures Dashboard
The dashboard has also been updated to reflect the below refinement(s) for:
| Measure | Description | |
|---|---|---|
| MIPS #134: Preventive Care and Screening | The 2024 measure specification no longer considers a diagnosis of depression as an exclusion. The exclusion criteria will be updated to reflect this. The denominator exclusion reason will be updated to, “Patients who have ever been diagnosed with bipolar disorder”. | Practices may notice a slight difference due to patients with a diagnosis of depression no longer being excluded. |
MIPS Promoting Interoperability Dashboard
On Monday, April 8, 2024, YTD 2024 data can be accessed from the Time Period dropdown, and, by default, the dashboard will show the latest 90-day period in 2024.
Status of Dashboard Updates for 2024
CMS releases updates to the quality measure specifications annually for the MIPS program. These measure specifications have been reviewed, and Practice Insights is working on the required technical updates to align with the revised requirements. McKesson will continue to notify practices once measures have been updated based on the current 2024 requirements. The measures listed below either have no 2024 update required or have been updated.
| Measure | Description |
|---|---|
MIPS Quality Measures Dashboard |
|
| #128 | BMI (This measure is no longer a MIPS Traditional Measure) |
| #130 | Current Medications |
| #134 | Preventive Care and Screening for Depression and Follow-Up Plan |
| #143 | Pain Intensity Quantified |
| #374 | Closing the Referral Loop |
| #462 | Bone Density Evaluation for Patients with Prostate Cancer and Receiving Androgen Deprivation Therapy |
|
PIMSH#1 |
Advance Care Planning in Stage 4 Disease |
| PIMSH#2 | Utilization of GCSF in Metastatic Colon/Rectal Cancer (Inverse Measure) |
| PIMSH#4 | Patient-Reported Pain Improvement |
| PIMSH#9 | Supportive Care Drug Utilization in the Last 14 Days of Life (Inverse Measure) |
| PIMSH#10 | Hepatitis B Serology Testing for Prophylactic Treatment Prior to Receiving Anti-CD20 Targeting Drugs |
|
PIMSH#15 |
Antiemetic Therapy for Low-and-Minimal-Emetic Risk Antineoplastic Agents in the Infusion Center-Avoidance of Overuse (Inverse Measure) |
|
PIMSH#16 |
Appropriate Antiemetic Therapy for High-and Moderate-Emetic-Risk Antineoplastic Agents in the Infusion Center |